Efficacy of Intra-Tympanic Dexamethasone on prevention of Ototoxicity in patients on Cisplatin therapy

Not Applicable

Recruiting

• Conditions: Cancer; Ear, Nose and Throat; Ototoxicity, Solid Cancers

• Registration Number: PACTR201707002355147
• Lead Sponsor: COLLEGE OF MEDICINE

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-06-14
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

Patients with solid cancers on cisplatin based chemotherapy

Exclusion Criteria

1. Severely ill patients who cannot undergo the hearing examination.
2. Pathological findings on otoscopy that do not allow safe ITD delivery
3. Previous inner ear disease with resultant sensorineural hearing loss
4. Conductive hearing loss >5 dBHL
5. Pure tone thresholds average (PTA) >40 dBHL for the frequencies 500 to 3000 Hz or 4000 to 8000 Hz16
6. Asymmetry of PTA between the ears >10 dBHL for the frequencies 500 to 3000 Hz or 4000 to 8000 Hz16
7. Previous treatment with Cisplatin
8. History of radiation therapy (or planned concurrent radiation therapy) to the head and neck regions.

Study & Design

• Study Type: Interventional
• Study Design: Not specified